{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:07:49Z","timestamp":1792066069677,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","award":["3170813"],"award-info":[{"award-number":["3170813"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpba.2025.116757","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T11:55:35Z","timestamp":1739793335000},"page":"116757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Development and validation of stability-indicating UHPLC-UV-MS tandem methods for lenalidomide assay, related substances, and genotoxic impurity monitoring"],"prefix":"10.1016","volume":"258","author":[{"given":"\u00c7a\u011fan","family":"A\u011fta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Bellur Atici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116757_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119771","article-title":"Lenalidomide and pomalidomide inhibit growth of prostate stromal cells and human prostate smooth muscle contraction","volume":"281","author":"Tamalunas","year":"2021","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.jpba.2025.116757_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41571-021-00479-z","article-title":"Cancer therapies based on targeted protein degradation \u2013 lessons learned with lenalidomide","volume":"18","author":"Jan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jpba.2025.116757_bib3","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-023-40385-9","article-title":"Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation","volume":"14","author":"Yamanaka","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpba.2025.116757_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1570-0232(04)00666-X","article-title":"Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography\u2013mass spectrometry","volume":"811","author":"Tohnya","year":"2004","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.jpba.2025.116757_bib5","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1039\/c2an36701g","article-title":"Development and validation of LC\u2013MS\/MS method for the quantitation of lenalidomide in human plasma using Box\u2013Behnken experimental design","volume":"138","author":"Hasnain","year":"2013","journal-title":"Analyst"},{"key":"10.1016\/j.jpba.2025.116757_bib6","doi-asserted-by":"crossref","first-page":"98600","DOI":"10.1039\/C5RA22339C","article-title":"Simultaneous determination of dexamethasone and lenalidomide in rat plasma by solid phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetic studies","volume":"5","author":"Maher","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2025.116757_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2016.06.009","article-title":"LC\u2013MS\/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients","volume":"1028","author":"Shu","year":"2016","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.jpba.2025.116757_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1752-153X-6-118","article-title":"A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine","volume":"6","author":"Darwish","year":"2012","journal-title":"Chem. Cent. J."},{"issue":"5","key":"10.1016\/j.jpba.2025.116757_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1080\/10826071003608777","article-title":"Degradation studies of highly potent and life threatening human birth defect drug\u2013lenalidomide by HPLC and LC-MS","volume":"33","author":"Raghu","year":"2010","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2025.116757_bib11","unstructured":"ICH Guideline Q3B (R2), Step 5, Impurities in new drug products, European Medicines Agency, CPMP\/ICH\/2738\/99, June 2006, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-3-b-r2-impurities-new-drug-products-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116757_bib12","unstructured":"ICH Q2 (R2) Guideline on validation of analytical procedures, Step 5, European Medicines Agency, EMA\/CHMP\/ICH\/82072\/2006, December 2023, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116757_bib13","unstructured":"ICH Guideline Q1A (R2), Step 5, Stability testing of new drug substances and products, European Medicines Agency, CPMP\/ICH\/2736\/99, August 2003, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116757_bib14","unstructured":"ICH Guideline Q1B, Step 4, Stability testing: Photostability testing of new drug substances and products Q1B, International Conference on Harmonisation, January 1998, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-b-photostability-testing-new-active-substances-and-medicinal-products-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116757_bib15","unstructured":"ICH M7 (R2) Guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, Step 5, European Medicines Agency, EMA\/CHMP\/ICH\/83812\/2013, July 2023, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m7r2-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2025.116757_bib16","first-page":"1","article-title":"Synthesis, characterization and control of eight process related and two genotoxic fingolimod impurities by a validated RP-UPLC method","author":"Bellur Atici","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.116757_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115220","article-title":"The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products","volume":"225","author":"Hatokova","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115525","article-title":"Study on the degradation and pyrolysis of 2-fluoromethcathinone","volume":"234","author":"Luo","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115568","article-title":"The first RP-UHPLC method for simultaneous quantification of abiraterone acetate, its four degradants, and six specified process impurities and correct identification of all analytes based on molecular weight","volume":"234","author":"Mhaske","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115845","article-title":"Investigation of aclidinium bromide degradation by stability-indicating HPLC methods, characterization of impurities by NMR, and identification of degradation products by LC-MS","volume":"238","author":"Yazar","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116000","article-title":"Quantitative determination of potential genotoxic impurities in metformin hydrochloride and empagliflozin tablets through ultra-performance liquid chromatography mass spectrometry","volume":"241","author":"Xiao","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116303","article-title":"Investigation into the genotoxic impurity, 1-methyl-4-nitrosopiperazine, in rifampicin","volume":"248","author":"Tian","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116274","article-title":"Determination of nitrobenzene potential genotoxic impurities in nifedipine with GC-MS","volume":"248","author":"Zhao","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116757_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-011-1760-3","article-title":"Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects","volume":"69","author":"Chen","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116757_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-012-2040-6","article-title":"Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration","volume":"71","author":"Hoffmann","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116757_bib27","first-page":"352","article-title":"The metabolism of thalidomide: some biological effects of thalidomide and its metabolites","volume":"25","author":"Fabro","year":"1965","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116757_bib28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2174\/138920006778017777","article-title":"Thalidomide metabolism and hydrolysis: mechanisms and implications","volume":"7","author":"Lepper","year":"2006","journal-title":"Curr. Drug Metab."},{"issue":"11","key":"10.1016\/j.jpba.2025.116757_bib29","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-\u03b1 production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jpba.2025.116757_bib30","unstructured":"Public Assessment Report, Scientific discussion, Lenalidomide, SE\/H\/2033\/01-05\/DC, \u3008https:\/\/docetp.mpa.se\/LMF\/Lenalidomide%20Orion%20capsule%2C%20hard%20ENG%20PAR_09001bee83177db0.pdf\u3009."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T15:45:51Z","timestamp":1763999151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"alternative-id":["S0731708525000986"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116757","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of stability-indicating UHPLC-UV-MS tandem methods for lenalidomide assay, related substances, and genotoxic impurity monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116757","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116757"}}